Onyx Pharmaceuticals Inc.

Gregory J. Giotta, Ph.D., J.D., joined Onyx in June 1995 as Vice President and Chief Legal Counsel. Prior to joining the company, he served as Vice President and Chief Intellectual Property Attorney at Glycomed Corporation from 1992 to 1995. Previously, Dr. Giotta held various positions at Cetus Corporation from 1990 to October 1992, including Director of Patents and Trademarks for therapeutics. He earned his Ph.D. from the University of California at Santa Cruz, and his J.D. from the University of San Diego. Dr. Giotta also pursued post-doctoral research at Harvard University and The Salk Institute.

Laura A. Brege joined Onyx in June 2006 as Executive Vice President & Chief Business Officer. In that role, she oversaw the expansion of key corporate capabilities and strengthened Onyx’s financial position by significantly adding to its cash reserves. She was promoted to her current position in October 2007 and is responsible for the sales and marketing, medical affairs, legal, and compliance functions. Before joining Onyx, Ms. Brege was a general partner at Red Rock Management, a venture capital firm. Prior to Red Rock, she was the Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago. Ms. Brege serves on the boards of Angiotech Pharmaceuticals, Inc. and The Ohio University Foundation.

Matthew Fust has served as a member of our board of directors since 2005. Mr. Fust is the Chief Financial Officer of Jazz Pharmaceuticals, a pharmaceutical company. From May 2002 to May 2003, Mr. Fust was Chief Financial Officer at Perlegen Sciences, Inc., a biotechnology company. From June 1996 to January 2002, he was an executive with ALZA Corporation, first as Controller and then as Chief Financial Officer. Mr. Fust holds an M.B.A. from the Stanford Graduate School of Business and a Bachelor's degree in Accounting from the University of Minnesota.

Paul K. Ross has served as Onyx's Vice President and Chief Compliance Officer since October 2007 and prior to that was Senior Director, Chief Compliance Officer with Onyx beginning in July 2005. From 2002 to 2005, Mr. Ross served in an escalation of compliance officer roles at Chiron Corporation where he established and provided oversight to commercial, business unit, and corporate compliance programs. Previously, Mr. Ross held various management roles in Regulatory Affairs with InterMune, Inc. and Pharmacia Corporation. Mr. Ross earned his undergraduate degree in Biological Sciences from the University of California, Santa Barbara and his MBA from the University of Phoenix, Pleasanton.

Juergen Lasowski, Ph.D., joined Onyx in May 2008 as Senior Vice President of Corporate Development. Before joining Onyx, Dr. Lasowski was the Senior Vice President of Corporate Development at NPS Pharmaceuticals. Previously, Dr. Lasowski held several positions at Sanofi-Aventis and its predecessor companies, mainly Business Development and Strategy positions. Throughout his career, Dr. Lasowski has completed over 25 different business transactions and worked on three continents including North America, Europe and Asia. Dr. Lasowski earned his MBA from INSEAD, France, and his Ph.D. in organic chemistry from the University of Mainz, Germany.

Judy Batlin has served as Onyx's Vice President of Organizational Learning, Development, and Human Resources since February 2008, and had previously served as an organization development consultant at Onyx since 2005. Ms. Batlin specializes in developing leadership competencies and overall effectiveness of teams and individual employees. She has over twenty years of experience in the biotechnology and pharmaceutical industry, and during her career has collaborated with a variety of organizations such as Acologix, Exelixis, Iconix Pharmaceuticals, Genentech, Pharmacopeia, Celera, Stanford Medical Center and Clinics, Chiron, and Berlex. Earlier in her career, Ms. Batlin served as Director of Organizational Learning, as well as Director of Staffing and Employee Relations for Chiron Corporation. Previously, she held the position of Associate Director of Human Resource Development at Berlex Laboratories.

Array

Patricia A. Oto, R.Ph., joined Onyx in December 2006 as the Vice President of Regulatory Affairs. From 2001 until 2006, Ms. Oto was at Anesiva, Inc., most recently as Vice President of Regulatory Affairs and Quality Assurance. While there, she provided strategic management and oversight for all regulatory submissions and Quality Assurance activities. Prior to joining Anesiva, Inc., Ms. Oto was the Senior Director of Regulatory Affairs at Corixa Corporation following its acquisition of Coulter Pharmaceuticals. While at Coulter, she was the Director of Regulatory Affairs and Quality Assurance. Previously, Ms. Oto held various regulatory positions at Genentech, Inc. She received her B.S. in Pharmacy from the University of New Mexico College of Pharmacy.

Michael J. Berendt, Ph.D., 59, has served as a Director of the Company since March 1998. Dr. Berendt is the President and Chief Executive Officer of Aegera Therapeutics Inc., a position he assumed in March 2006. From August 2004 to December 2005, Dr. Berendt served as Managing Director of Research Corporation Technologies. From November 2000 to August 2004, Dr. Berendt served as Managing Director of AEA Investors. Dr. Berendt also worked for 18 years, from 1982 to 2000, in the pharmaceutical industry where he served in a number of senior management positions including Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation, and a Group Director of Drug Discovery at Pfizer, Inc. Dr. Berendt has served as a member of the Board of Directors of Onyx Pharmaceuticals, Myriad Genetics, Inc., Catalyst Biosciences and Northstar Neuroscience.

Dr. Goddard has served as the chairman of our board of directors since August 2003 and was appointed our chief executive officer in April 2005. From March 2000 and August 2005, Dr. Goddard served as chairman and part-time executive of several companies including A.P. Pharma, Inc., a pharmaceutical company, and XenoPort, Inc., a biopharmaceutical company. From October 1998 until March 2000, he was chief executive officer of Elan Pharmaceuticals, Inc., the largest division of Elan Corporation plc, a biotechnology company. He was chief executive officer of Neurex Corporation, a biotechnology company, from February 1991 until October 1998 when the company was acquired by Elan Corporation plc. Prior to 1991, Dr. Goddard held various senior management positions at SmithKline Beecham plc, a pharmaceutical company, including senior vice president strategic marketing and senior vice president Far East region. He obtained his doctorate degree from St. Mary's Hospital, London, in the area of etiology and pathophysiology of colon cancer. Dr. Goddard remains on the board of directors of A.P. Pharma, Inc., Adolor Corporation, a biopharmaceutical company, and Onyx Pharmaceuticals, Inc., a biopharmaceutical company.

Robert L. Jones is a partner in Cooley Godward Kronish's Business department. He has been located in the Firm's Palo Alto office since it opened in 1980. Previously, he served as the Firm's Business department chair from 2002 to 2004 and chair of the Firm's Life Sciences practice from 2000 to 2002. Mr. Jones has a broad corporate law practice devoted to the representation of technology companies, and particularly companies in the life sciences industries. His practice includes the full range of corporate and securities law matters, including public and private financings, advice regarding disclosure issues and securities law compliance, and fiduciary issues. Mr. Jones is one of the country's leading practitioners for the representation of biotechnology companies. He is particularly well known for his work in the field of licensing and corporate partnering transactions, and is a frequent lecturer of this topic. His biotechnology clients include, by way of example, Five Prime Therapeutics, Exelixis, Gilead Sciences, Kosan Biosciences, Nektar Therapeutics, and Onyx Pharmaceuticals. Mr. Jones was also the primary outside counsel for COR Therapeutics prior to its acquisition. In 1979, Mr. Jones received a J.D. degree from Stanford Law School, where he was elected to Order of the Coif, and an M.B.A. degree from Stanford Graduate School of Business, where he received the Henry Ford II Scholar award for highest academic achievement. He also served as managing editor of the Stanford Journal of International Studies. Mr. Jones received a B.A. degree in 1975 from Swarthmore College, with a major in economics.